InBiome is at the forefront of molecular diagnostics, particularly through its innovative Molecular Culture technology, which significantly enhances the speed and accuracy of bacterial diagnostics and microbiome analysis. This proprietary method allows for the detection of a wide range of bacteria, including those that are unknown, uncultivable, or antibiotic-treated, without the need for prior selection. As a result, diagnoses can be completed within hours rather than days, leading to quicker patient recovery, reduced complications, and shorter hospital stays. The technology has been optimized for various applications, including infectious disease diagnostics in joint aspirates, demonstrating its versatility and effectiveness in improving healthcare outcomes.

In addition to its diagnostic capabilities, InBiome emphasizes research and development as a core aspect of its operations. The company collaborates with universities and hospitals to explore new avenues in bacterial diagnostics and microbiome-based healthcare. Their team, composed of microbiologists, biomedical scientists, bioinformaticians, and AI specialists, is dedicated to advancing the understanding of microbial populations and their functions. InBiome also offers microbiome analysis solutions and reporting services, enabling researchers to assess the impact of treatments on the microbiome and gain valuable insights into their research questions. This comprehensive approach positions InBiome as a leader in the field, committed to driving innovation and improving patient care through advanced molecular technologies.

Netherlands

By combining machine learning with advanced chemistry, inBiome enables microbiology labs over the world to rapidly and easily identify bacteria in a wide range of clinical sample types, including complex microbiota. Even uncultivable- and antibiotics treated species are detected. Current applications include replacing traditional culture in ICU’s for more accurate, same day results, infection control, gut flora analysis and various r&d applications for healthcare, pharmacy and food industies. Promising new applications currently undergoing clinical trials include IBD and Sepsis dagnostics and preventive screening.

InBiome

Company Details